Cel-Sci Corporation (CVM)
| Market Cap | 191.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -36.01M |
| Shares Out | 43.33M |
| EPS (ttm) | -0.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 243,494 |
| Open | 4.36 |
| Previous Close | 4.45 |
| Day's Range | 4.22 - 4.44 |
| 52-Week Range | 2.49 - 12.90 |
| Beta | 2.16 |
| Analysts | Buy |
| Price Target | 15.30 (+246.2%) |
| Earnings Date | Aug 15, 2022 |
About CVM
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and ... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for CVM stock is "Buy." The 12-month stock price forecast is 15.3, which is an increase of 246.15% from the latest price.
News
CEL-SCI Corporation to Present at LD Micro Invitational
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation to Present at LD Micro Invitational.
CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ASCO22--CEL-SCI presents Phase 3 Multikine head and neck cancer data at ASCO.
CEL-SCI Announces Publication of ASCO 2022 Abstracts
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces publication of ASCO 2022 abstracts.
CEL-SCI Corporation Reports Second Quarter Fiscal 2022 Financial Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI corporation reports second quarter fiscal 2022 financial results.
CEL-SCI Announces Acceptance of Abstracts to ASCO 2022
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces acceptance of abstracts to ASCO 2022.
3 Penny Stocks to Watch With Above Average Volume Today
Are these high-volume penny stocks on your buy list right now? The post 3 Penny Stocks to Watch With Above Average Volume Today appeared first on Penny Stocks to Buy, Picks, News and Information | Penn...
CEL-SCI Corporation Reports First Quarter Fiscal 2022 Financial Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports first quarter fiscal 2022 financial results.
CEL-SCI Reports Fiscal 2021 Financial Results and Clinical & Corporate Developments
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal 2021 financial results and clinical & corporate developments.
CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing Facility
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation completes commercial-scale buildout of Multikine manufacturing facility.
CEL-SCI Corporation Reports Third Quarter Fiscal 2021 Financial Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports third quarter fiscal 2021 financial results.
Why CEL-SCI Stock Soared Today
The company attempted to clarify "confusion" related to its recent late-stage clinical results.
CEL-SCI Corporation Issues Letter to Shareholders
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #HeadandNeckCancer--CEL-SCI Corporation issues letter to shareholders.
3 Biotechs to Avoid Like the Plague in July
Generally speaking, biotech is a pretty innovative industry -- with a few notable bad apples.
Discussion of Results of CEL-SCI's Phase 3 Trial Is Now Available
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #HeadandNeckCancer--The discussion of the results of CEL-SCI's Phase 3 Trial is now available.
Why CEL-SCI Shares Are Getting Hammered Today
CEL-SCI Corporation (NASDAQ:CVM) shares are trading lower by 27% at $9.33 on continued downward momentum following data from a Phase 3 Study of Multkine showing a 14.1% 5-year survival benefit in groups...
CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021
Will All End Well for This Popular Reddit Biotech?
Everything went the wrong way for Cel-Sci.
CVM Stock: The Big Trial News That Has Cel-Sci Plunging Today
Today, the trial results reported by Cel-Sci missed the mark, and investors are pricing in additional risks with CVM stock. The post CVM Stock: The Big Trial News That Has Cel-Sci Plunging Today appeare...
CEL-SCI's Immunotherapy Achieves Survival Benefit Of 14% Exceeding Pre-Defined 10% In Head & Cancer Patients
CEL-SCI Corporation (NYSE: CVM) has announced results from its Phase 3 study for its immunotherapy Multikine for advanced previously untreated squamous cell carcinoma of the head and neck (SCCHN). In th...
CEL-SCI's Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group R...
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Multikine immunotherapy produces significant 14.1% 5-Year survival benefit in group receiving surgery plus radiotherapy in landmark Phase 3 Study.
CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder Meeting
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI Corporation invites participants to pre-submit questions for Annual Shareholder Meeting.
CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces the closing of $31.7 million bought deal offering.
CEL-SCI Stock Drops After Raising $37.1M Via Secondary Equity Offering
CEL-SCI Corporation (NYSE: CVM) has increased the size of its previously announced capital raise offering to 1.4 million shares, up from 1 million shares, at $22.62 per share representing a 5% discount ...
CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million.
CEL-SCI Announces Bought Deal Offering
VIENNA, Va.--(BUSINESS WIRE)-- #CVM--CEL-SCI Announces Bought Deal Offering